Cutaneous, oral and genital lichenoid reactions associated with retifanlimab, a new <scp>PD</scp> ‐1 inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cutaneous, oral and genital lichenoid reactions associated with retifanlimab, a new PD ‐1 inhibitor

Published:2022-12-03 Issue:3 Volume:37 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

van Damme Claire¹^ORCID,Demols Anne²,del Marmol Veronique¹^ORCID

Affiliation:

1. Department of Dermatology, CUB Hôpital Erasme – Brussels University Clinics Université Libre de Bruxelles Brussels Belgium

2. Department of Gastroenterology and GI Oncology, CUB Hôpital Erasme – Brussels University Clinics Université Libre de Bruxelles Brussels Belgium

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18785

Reference10 articles.

1. Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management

2. Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description

3. Lichenoid drug eruption on the lower lip caused by anti-PD-1 monoclonal antibody: a case report and literature review

4. Recurrent bilateral cutaneous squamous cell carcinoma arising within hypertrophic lichen planus with metastasis while on cemiplimab

5. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary adrenocortical insufficiency after treatment with retifanlimab: a case report;Frontiers in Immunology;2024-06-10

2. Anogenital lichenoid lesions: clinicopathological features and differential diagnosis;Diagnostic Histopathology;2024-01

3. Carboplatin/paclitaxel/retifanlimab;Reactions Weekly;2023-09-16

4. Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review;Current Molecular Medicine;2023-06-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3